New Drug Combo for ALS Slows Decline in Small Clinical Study
New Drug Combo for ALS Slows Decline in Small Clinical Study
After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.
New Drug Combo for ALS Slows Decline in Small Clinical Study
New Drug Combo for ALS Slows Decline in Small Clinical Study

After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.

After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.

ALS
Breaking Down Barriers
Breaking Down Barriers
The Scientist Creative Services Team | Oct 19, 2020
Looking at the future of neurodegeneration research!
Symptoms in ALS Mouse Model Improve with CRISPR Base Editing
Symptoms in ALS Mouse Model Improve with CRISPR Base Editing
Abby Olena | Apr 10, 2020
Researchers slowed disease progression in the mice by injecting two different viral vectors, each containing one part of the DNA encoding the Cas9 protein, to edit the causative gene.
“Hero” Proteins May Shield Other Proteins from Harm
“Hero” Proteins May Shield Other Proteins from Harm
Emma Yasinski | Mar 19, 2020
Flexible proteins appear to protect molecules from becoming denatured in extreme conditions such as heat and from clumping up, as happens in some neurodegenerative diseases.
Those We Lost in 2019
Those We Lost in 2019
Ashley Yeager | Dec 30, 2019
The scientific community said goodbye to Sydney Brenner, Paul Greengard, Patricia Bath, and a number of other leading researchers this year.
Commensal Bacterium Reduces ALS Symptoms in Mice
Commensal Bacterium Reduces ALS Symptoms in Mice
Jef Akst | Jul 24, 2019
Boosting the levels of Akkermansia muciniphila in mouse guts slowed the progression of an ALS-like disease, while two other microbiome members were associated with more severe symptoms.
Neuroscientist Rahul Desikan Dies
Neuroscientist Rahul Desikan Dies
Kerry Grens | Jul 19, 2019
He developed an MRI-based map of the human cortex, discovered genetic risk factors for neurodegenerative diseases, and wrote about his struggles with ALS.
Infographic: Human Endogenous Retroviruses and Disease
Infographic: Human Endogenous Retroviruses and Disease
Katarina Zimmer | Jan 1, 2019
Human endogenous retroviruses that colonized vertebrate DNA millions of years ago have long been dismissed as junk DNA, but researchers now know that they may play important roles in cancer, neurodegeneration, and other ailments.
Can Viruses in the Genome Cause Disease?
Can Viruses in the Genome Cause Disease?
Katarina Zimmer | Jan 1, 2019
Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.
Those We Lost in 2018
Those We Lost in 2018
Ashley Yeager | Dec 26, 2018
The scientific community said goodbye to a number of leading researchers this year.
CRISPR Corrects RNA-based Disease Defects
CRISPR Corrects RNA-based Disease Defects
Kerry Grens | Aug 10, 2017
In human cells, researchers deploy the genome editor to snip out toxic repetitive sequences.
Additional #IceBucketChallenge Payoffs
Additional #IceBucketChallenge Payoffs
Jef Akst | Jul 28, 2016
Researchers identify a new ALS-associated gene thanks to funds generated by the social media challenge that went viral in summer 2014.
Book Review: <em>Personal Trials</em>
Book Review: Personal Trials
Arthur L. Caplan | Mar 22, 2016
At first blush, do-it-yourself clinical trials seem pointless and reckless. But a deeper truth pervades the research and the patients who drive it forward.
Formaldehyde Fears
Formaldehyde Fears
Jef Akst | Oct 1, 2015
Data on the links between ALS and the chemical have been contradictory, but the latest study suggests undertakers are at risk.
Undertaker's Bane
Undertaker's Bane
The Scientist Staff | Sep 30, 2015
Harvard Professor Marc Weisskopf discusses the potential link between formaldehyde and ALS.
ALS Drug Access Debated
ALS Drug Access Debated
Jef Akst | Apr 7, 2015
Biotech company Genervon has requested accelerated approval for its experimental ALS drug after a small but promising Phase 2 trial. Patients advocate for its acceptance, while researchers urge caution.
Beneficial Stats
Beneficial Stats
Aimee Swartz | Mar 1, 2015
Statisticians who normally crunch numbers to forecast trends in the food-service industry turn their attention to bettering treatment of ALS.
#IceBucketChallenge Highlights Difficult Funding Decisions
#IceBucketChallenge Highlights Difficult Funding Decisions
Jef Akst | Sep 3, 2014
The ALS Association has raised more than $100 million in donations through a charity campaign that went viral. How should that money be spent?
Ice Bucket Challenge Irony
Ice Bucket Challenge Irony
Bob Grant | Aug 25, 2014
Several US legislators who voted in favor of a bill that cut federal funding for ALS research have taken the chilly plunge for charity.
Non-coding Repeats Cause Peptide Clumps
Non-coding Repeats Cause Peptide Clumps
Ruth Williams | Feb 7, 2013
Protein aggregates in the brains of some people with dementia or motor neuron disease have a surprising origin.